Nodality’s SCNP Platform Holds Strong Potential in Aiding the
Development of New Cancer and Immuno-Oncology Treatments
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Nodality, Inc., an innovative biotechnology company advancing discovery,
development and use of transformative therapies by revealing functional
systems biology, announced today promising data utilizing the company's
proprietary Single Cell Network Profiling (SCNP)
technology in metastatic melanoma. Nodality’s SCNP technology reveals
functional biology underlying the most important and intractable
diseases, providing critical insights to help guide the discovery and
development of next-generation therapeutic agents. According to data
published in the current issue of the Journal of Translational
Medicine (JTM), Nodality’s researchers have identified key
biomarkers in the blood that can help predict responses to new therapies
for melanoma, including cancer immunotherapeutics.
“While there has been exciting recent progress in the treatment of
melanoma, new therapies have been found to benefit only a subset of
patients and are often associated with significant adverse effects,”
commented Laura Brege, Nodality’s President and Chief Executive Officer.
“With our highly sensitive and reproducible SCNP platform, we are able
to attain a deep, functional understanding of how the immune system
behaves in the presence of tumor cells and how cancer cells vary in
their response to approved and promising development-stage therapies. In
light of SCNP’s broad range of capabilities and potential applications,
we believe our technology can play an essential role in advancing
pipelines of targets and therapeutics to deliver the next generation of
drugs for cancer and other major illnesses.”
For access to the JTM article, titled “Systems biology analysis of
immune signaling in peripheral blood mononuclear cells (PBMC) of
melanoma patients receiving ipilimumab; basis for response biomarker
identification,” please visit http://www.translational-medicine.com/content/12/S1/O13.
About Single Cell Network Profiling
Contemporary pharmaceutical research and development remains challenged
in producing drugs to revolutionize the treatment of many of our most
intractable diseases, such as cancer, autoimmune diseases, and diseases
of the cardiovascular system and central nervous system, demanding
higher levels of biological understanding to inform effective drug
development decisions. Nodality’s proprietary Single Cell Network
originally developed at Stanford University, is a multiparametric flow
cytometry-based assay that provides unprecedented insights into diseases
by characterizing cell signaling networks in millions of cells at the
single cell level. SCNP measures functional protein pathway signaling
networks within and between cells, identifying rare cell subsets, such
as drug-resistant cells, revealing epigenetic changes in cells, and
perceiving cell-cell interactions in complex disease states.
Nodality is advancing drug discovery, therapeutic development, and
precision medicine by delivering critical and clinically actionable
information to bridge gaps left by traditional R&D approaches.
Nodality’s proprietary functional biology platform, Single Cell Network
Profiling (SCNP), unlocks highly complex intracellular mechanisms and
cellular interactions in human diseases and has the power to shed light
on some of the pharmaceutical industry’s most challenging R&D problems.
SCNP enables smarter spending decisions and is applicable across a very
broad therapeutic landscape and throughout the full discovery and
development process. Nodality has established multi-year strategic
collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer
(NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP
technology to assist the development of new therapeutic compounds.
212-213-0006, ext. 327
Source: Nodality, Inc.